Cetera Advisor Networks LLC Has $14.31 Million Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Cetera Advisor Networks LLC boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,853 shares of the medical equipment provider’s stock after buying an additional 568 shares during the quarter. Cetera Advisor Networks LLC’s holdings in Intuitive Surgical were worth $14,309,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Provence Wealth Management Group bought a new stake in Intuitive Surgical during the fourth quarter worth approximately $276,000. Sequoia Financial Advisors LLC grew its stake in Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in Intuitive Surgical by 5.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after acquiring an additional 9,869 shares during the period. HCR Wealth Advisors lifted its position in Intuitive Surgical by 26.3% during the 4th quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after acquiring an additional 217 shares during the last quarter. Finally, Kades & Cheifetz LLC bought a new stake in Intuitive Surgical during the fourth quarter valued at about $230,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.3 %

Shares of Intuitive Surgical stock traded down $1.21 during mid-day trading on Friday, reaching $449.73. 2,059,603 shares of the stock were exchanged, compared to its average volume of 1,844,110. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $468.78. The company has a market cap of $159.52 billion, a price-to-earnings ratio of 81.18, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39. The firm has a 50-day simple moving average of $432.13 and a 200 day simple moving average of $401.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted $1.18 earnings per share. On average, research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the sale, the senior vice president now directly owns 883 shares in the company, valued at $343,628.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, SVP Mark Brosius sold 175 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the sale, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,062 shares of company stock valued at $5,589,790. 0.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on ISRG. BTIG Research boosted their price objective on Intuitive Surgical from $451.00 to $459.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Piper Sandler increased their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Evercore ISI reduced their price target on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a report on Friday, July 19th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $442.30.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.